EXSCIENTIA
3.11.2022 12:01:52 CET | Business Wire | Press release
Exscientia plc (Nasdaq: EXAI) today announced the expansion of its platform to include the design of biologics, such as human antibodies. The Company has progressed AI-driven capabilities for virtual biologics design throughout the year and is now establishing an automated biologics laboratory in Oxford to internally generate and profile novel antibodies.
“Exscientia is integrating biologics design into the modular architecture of our end-to-end, patient-first AI platform. Having demonstrated the ability of our existing precision medicine patient tissue models to analyse novel antibodies, we believe the addition of this biologics design capability will create one of the most powerful antibody platforms available,” said Professor Andrew Hopkins, Exscientia's founder and Chief Executive Officer. “Our balanced business model allows us to advance our pipeline programmes while also investing in platform growth. Expanding into biologics enables us to nearly double the addressable target universe of our platform. Over the past two years, antibodies represented eighteen of the top fifty drugs measured by revenue, and by adding the capability to design new human antibodies with AI and automation, we believe we will be able to develop the most effective drug for patients, regardless of modality.”
Current approaches to optimise antibodies, even those that use machine learning, still depend on discovering antibodies by experimental screening methods. Combining generative AI design and virtual screening of biologics would allow investigation of a broader antibody space and support Exscientia’s goal to design all of its biologics de novo for specific target epitopes without the need for screening.
In order to design novel antibodies against specific protein epitopes, it is necessary to generate accurate models of their structure at speed and scale. Initial versions of the technology invented by Professor Charlotte Deane, Exscientia’s Chief Scientist of Biologics AI, produced accurate protein modelling up to 35,000 times faster than Alphafold2 (Abanades et al. Bioinformatics 2021). Exscientia has significantly expanded the scope, speed and integration of these algorithms while also integrating the capabilities into its broader platform. Exscientia’s virtual screening methodology for antibodies is now over three times more accurate than the published state of the art.
Key to Exscientia’s AI approach is using the knowledge of the observed human antibody space to optimise biologics for clinical development. The binding site of the antibody consists of two chains (heavy and light). Typically, sequencing of antibodies has been limited to single chains, losing the true biology of antibodies. The Company is building a proprietary database of paired chain sequences to better understand the complex biology of antibodies in a more natural environment. Exscientia is using this data for machine learning in order to describe and model human antibody space more accurately.
Exscientia’s new laboratory facilities, which add an additional 8,000 square feet to its headquarters in the Oxford Science Park, will automate the production of proprietary data for each antibody, measuring essential qualities including affinity, immunogenicity, aggregation and stability. Exscientia’s engineers are building proprietary automation hardware to enable high-throughput antibody profiling to support its predictive model building for multi-parameter optimisation.
“Our strategy is to replace current experimental discovery techniques with precision engineered de novo design of optimised, fully-human biologics,” said Professor Charlotte Deane MBE. “Current methods limit the discovery of new binding sites to what can be explored via animal immunisation or laboratory-based libraries. By virtually designing all aspects of a biologic in silico, we can explore a much broader target universe and create more precisely targeted therapeutics: Biologics by design not discovery, driven by AI and automated experiment, is our approach.”
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbour” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations for the progress of development of candidate molecules; timing and progress of, and data reported from, preclinical studies and clinical trials of Exscientia’s product candidates; Exscientia’s ability to generate novel insights into antibody design and to build hardware and other systems to support high-throughput biologics profiling; and Exscientia’s expectations regarding the expansion of its precision medicine platform and AI-driven drug discovery platform. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions, including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics, and in the endeavour of building a business around such product candidates. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005339/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abu Dhabi International Boat Show Opens This Week With World Premieres and Record Participation17.11.2026 09:27:00 CET | Press release
Held under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region, the Abu Dhabi International Boat Show (ADIBS) returns from 19 to 22 November 2026 at ADNEC Marina Hall for its eighth and largest edition yet, bringing together 1,210 exhibitors and brands from 57 countries, a 13% increase on 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116669938/en/ ADNEC Marina Hall - ADNEC Group, Abu Dhabi – United Arab Emirates (Photo: AETOSWire) Organised by ADNEC Group under the theme “Life on and Beyond the Water”, the show spans more than 96,000 square metres and will feature 168 boats on display in the marina. Additionally, luxury yachts, houseboats, leisure boats and marine sports equipment will be launched for the first time in the region. “This year’s edition is set to be the largest in the Show’s history, with strong growth across key performance indicators reflectin
Lakestar and Rochefort Asset Management Co-Lead Series A for Tiberius Aerospace at over $1 Billion Valuation17.11.2026 09:00:00 CET | Press release
Financing will accelerate production of long-range precision munitions and expand allied sovereign manufacturing capacity. Lakestar, a European technology investment firm and Rochefort Asset Management (Rochefort), a U.S. national security-focused investment firm licensed under the U.S. Department of War's Office of Strategic Capital (OSC) and the Small Business Administration (SBA), today jointly announced that they have co-led an $85 million Series A financing round for defense technology company Tiberius Aerospace, Inc. (Tiberius). The investment values Tiberius at more than $1 billion on a post-money basis making it the latest defense technology unicorn. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117903633/en/ Tiberius Aerospace becomes a defense tech unicorn The round attracted new investors including Dream Ventures and Aero X Ventures, alongside other institutional investors, with participation from existing inv
Tractivity Joins European Technology Group to Strengthen Stakeholder Engagement Across Europe17.11.2026 09:00:00 CET | Press release
European Technology Group (ETG), a long-term oriented European GovTech platform, welcomes Tractivity, a leading stakeholder relationship management software provider in Europe, to its family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117911743/en/ Tractivity Joins European Technology Group to Strengthen Stakeholder Engagement Across Europe The transaction marks the next stage of Tractivity’s development after sustained growth. The company serves more than 100 organisations across energy, utilities, healthcare, central and local government, regulators and transport in Europe. As part of ETG, Tractivity will build on its established brand, long-standing customer trust and clear product focus. ETG adds resources and know-how to accelerate product development and invest in AI capabilities that make stakeholder engagement more efficient. ETG’s European network will support Tractivity’s expansion across Europe and among en
Aqara Expands Smart Lighting Portfolio, Showing the Spatial Intelligence Control With the Lighting Transfer17.11.2026 09:00:00 CET | Press release
Six new lighting products bring vibrant indoor and outdoor illumination, seamless Apple Home compatibility, dual-protocol connection, and personalized automation powered by Aqara numerous portfolio Aqara, a global leader and pioneer in IoT, today announced the global launch of six new smart lighting products showcased at IFA 2026: the Floor Lamp T1, LED Downlight T2, LED Strip T2, LED Bulb T2 E12/E14, Outdoor String Lights H1, and Permanent Outdoor Lights H1. Spanning everyday illumination, immersive entertainment, and outdoor decoration, the expanded portfolio pairs advanced lighting technology and flexible connectivity with Aqara’s extensive range of smart home devices to create more responsive, personalized living spaces. Together, they bring Aqara’s vision of Spatial Intelligence into the home. In addition, all these six products can be seamlessly integrated into the Apple Home ecosystem, offering smooth across-platform usage experience. This press release features multimedia. View
FPT Rises in France’s Top 85 Technology Services Ranking, Recording Significant Revenue Growth in the Market17.11.2026 07:30:00 CET | Press release
Global technology corporation FPT has ranked 85th among France’s digital services and technology consulting companies in the KPMG France and Numeum’s 2026 ranking, climbing 20 places year-on-year. The advancement follows approximately 50% revenue growth in France, reflecting the company’s expanding business scale and strengthening competitive position in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116291751/en/ The annual ranking covers 175 digital services and engineering and technology consulting companies based on their 2025 revenue generated in France. Published alongside the ranking, KPMG and Numeum’s Grand Angle ESN & ICT study highlights a broader industry shift, with generative and agentic AI emerging as major forces reshaping business models across the French technology services market. FPT’s growth in France has been built on long-standing relationships with major enterprises and its expanding rol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
